Reaction Details |
| Report a problem with these data |
Target | Phosphatidylinositol 3-kinase catalytic subunit type 3 |
---|
Ligand | BDBM25028 |
---|
Substrate/Competitor | BDBM15235 |
---|
Meas. Tech. | Scintillation Proximity Assay |
---|
pH | 7.5±n/a |
---|
Temperature | 295.15±n/a K |
---|
IC50 | >10000±n/a nM |
---|
Citation | Folkes, AJ; Ahmadi, K; Alderton, WK; Alix, S; Baker, SJ; Box, G; Chuckowree, IS; Clarke, PA; Depledge, P; Eccles, SA; Friedman, LS; Hayes, A; Hancox, TC; Kugendradas, A; Lensun, L; Moore, P; Olivero, AG; Pang, J; Patel, S; Pergl-Wilson, GH; Raynaud, FI; Robson, A; Saghir, N; Salphati, L; Sohal, S; Ultsch, MH; Valenti, M; Wallweber, HJ; Wan, NC; Wiesmann, C; Workman, P; Zhyvoloup, A; Zvelebil, MJ; Shuttleworth, SJ The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem51:5522-32 (2008) [PubMed] Article |
---|
More Info.: | Get all data from this article, Inhibition_Run data, Solution Info, Assay Method |
---|
|
Phosphatidylinositol 3-kinase catalytic subunit type 3 |
---|
Name: | Phosphatidylinositol 3-kinase catalytic subunit type 3 |
Synonyms: | BC033004 | PI3K type 3 | PIK3C3 | PK3C3_HUMAN | Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) | Phosphatidylinositol 3-kinase p100 subunit | Phosphoinositide 3-Kinase (PI3K), Vps34 | Phosphoinositide-3-kinase class 3 | PtdIns-3-kinase type 3 | VPS34 | hVPS34 |
Type: | Enzyme |
Mol. Mass.: | 101551.30 |
Organism: | Homo sapiens (Human) |
Description: | Recombinant human Vps34 protein was expressed as monomeric GST-fusion and purified. |
Residue: | 887 |
Sequence: | MGEAEKFHYIYSCDLDINVQLKIGSLEGKREQKSYKAVLEDPMLKFSGLYQETCSDLYVT
CQVFAEGKPLALPVRTSYKAFSTRWNWNEWLKLPVKYPDLPRNAQVALTIWDVYGPGKAV
PVGGTTVSLFGKYGMFRQGMHDLKVWPNVEADGSEPTKTPGRTSSTLSEDQMSRLAKLTK
AHRQGHMVKVDWLDRLTFREIEMINESEKRSSNFMYLMVEFRCVKCDDKEYGIVYYEKDG
DESSPILTSFELVKVPDPQMSMENLVESKHHKLARSLRSGPSDHDLKPNAATRDQLNIIV
SYPPTKQLTYEEQDLVWKFRYYLTNQEKALTKFLKCVNWDLPQEAKQALELLGKWKPMDV
EDSLELLSSHYTNPTVRRYAVARLRQADDEDLLMYLLQLVQALKYENFDDIKNGLEPTKK
DSQSSVSENVSNSGINSAEIDSSQIITSPLPSVSSPPPASKTKEVPDGENLEQDLCTFLI
SRACKNSTLANYLYWYVIVECEDQDTQQRDPKTHEMYLNVMRRFSQALLKGDKSVRVMRS
LLAAQQTFVDRLVHLMKAVQRESGNRKKKNERLQALLGDNEKMNLSDVELIPLPLEPQVK
IRGIIPETATLFKSALMPAQLFFKTEDGGKYPVIFKHGDDLRQDQLILQIISLMDKLLRK
ENLDLKLTPYKVLATSTKHGFMQFIQSVPVAEVLDTEGSIQNFFRKYAPSENGPNGISAE
VMDTYVKSCAGYCVITYILGVGDRHLDNLLLTKTGKLFHIDFGYILGRDPKPLPPPMKLN
KEMVEGMGGTQSEQYQEFRKQCYTAFLHLRRYSNLILNLFSLMVDANIPDIALEPDKTVK
KVQDKFRLDLSDEEAVHYMQSLIDESVHALFAAVVEQIHKFAQYWRK
|
|
|
BDBM25028 |
---|
BDBM15235 |
---|
Name | BDBM25028 |
Synonyms: | 4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine | GDC-0941 | GDC0941 | US10112932, pictilisib | US10851091, Compound pictilisib |
Type | Small organic molecule |
Emp. Form. | C23H27N7O3S2 |
Mol. Mass. | 513.636 |
SMILES | CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1 |
Structure |
|